Cargando…

Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer

INTRODUCTION: Concurrent chemoradiotherapy (cCRT) was the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) prior to the PACIFIC trial, however, patients also received single modality therapy. This study identified predictors of therapy and differences in o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bobbili, Priyanka, Ryan, Kellie, DerSarkissian, Maral, Dua, Akanksha, Yee, Christopher, Duh, Mei Sheng, Gomez, Jorge E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080248/ https://www.ncbi.nlm.nih.gov/pubmed/32187231 http://dx.doi.org/10.1371/journal.pone.0230444

Ejemplares similares

Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study
por: Bobbili, Priyanka, et al.
Publicado: (2020)

Removal of ineligible outcome cases reduces confounding
por: Walker, Alexander M, et al.
Publicado: (2018)

Patient-centric assessment of rheumatoid arthritis using a smartwatch and bespoke mobile app in a clinical setting
por: Hamy, Valentin, et al.
Publicado: (2023)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States
por: DerSarkissian, Maral, et al.
Publicado: (2016)

CO103 Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the National COVID Cohort Collaborative (N3C)
por: Bell, C., et al.
Publicado: (2023)

Impact of neutrophil-to-lymphocyte ratio throughout the course of chemoradiotherapy on overall survival and distant failure in unresectable stage III non-small cell lung cancer
por: Kanzaki, Hiromitsu, et al.
Publicado: (2021)

2512. Decreasing Adherence to Antiretroviral Therapy over 4 Years of Follow-up in a Commercially-Insured Population of Patients with HIV
por: Priest, Julie, et al.
Publicado: (2019)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation
por: Nicolini, Franck E., et al.
Publicado: (2017)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2022)

Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
por: DerSarkissian, Maral, et al.
Publicado: (2023)

Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden
por: Huang, Shirley P, et al.
Publicado: (2023)

Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs
por: Apple, Jon, et al.
Publicado: (2023)

Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION study
por: Horinouchi, Hidehito, et al.
Publicado: (2020)

Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection
por: Yuan, Yan, et al.
Publicado: (2021)

Salvage surgery after definitive chemoradiotherapy through VATS for an initial unresectable locally advanced lung cancer: an alternative consolidative modality to radiotherapy?
por: Yu, Hsuan-Hsuan, et al.
Publicado: (2021)

Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy
por: Xu, Cai, et al.
Publicado: (2019)

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
por: Tang, Shi, et al.
Publicado: (2023)

Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis
por: Chang, Xiu-Jun, et al.
Publicado: (2016)

A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer
por: Gupta, Arunima, et al.
Publicado: (2014)

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)
por: Patel, Priyanka, et al.
Publicado: (2020)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Cellular based treatment modalities for unresectable hepatocellular carcinoma
por: Damiris, Konstantinos, et al.
Publicado: (2021)

Unresectable Extraskeletal Myxoid Chondrosarcoma of the Neck: Early Tumor Response to Chemoradiotherapy
por: Zaki, Mark, et al.
Publicado: (2015)

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study
por: Ouwens, Mario, et al.
Publicado: (2021)

1024. Real-world Adherence and Persistence with Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Compared to Oral Antiretroviral Therapy (ART) Among People with HIV (PWH) in the US: The ABOVE Study
por: Garris, Cindy, et al.
Publicado: (2023)

Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
por: Vrankar, Martina, et al.
Publicado: (2020)

Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy
por: Sakaguchi, Tadashi, et al.
Publicado: (2021)

Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2023)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study
por: Hu, Min, et al.
Publicado: (2020)

A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA
por: Bell, Christopher F., et al.
Publicado: (2022)

The Relationship between Social Capital and Quality Management Systems in European Hospitals: A Quantitative Study
por: Hammer, Antje, et al.
Publicado: (2013)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
por: Yu, Kenneth H., et al.
Publicado: (2021)

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma
por: Kim, Young-Il, et al.
Publicado: (2013)

Unresectable esophageal cancer treated with multiple chemotherapies in combination with chemoradiotherapy: A case report
por: Yura, Masahiro, et al.
Publicado: (2021)

The Impact of Weight Loss during Chemoradiotherapy for Unresectable Esophageal Cancer: Real-World Results
por: Huang, Tzu-Ting, et al.
Publicado: (2022)

Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma
por: Hirama, Nobuyuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ft3fadb4ielnf21g94kbldq8p2